U.S. job postings
fell in March
Employers posted fewer job openings in March, compared with February, and slowed overall hiring, underscoring a weak month of job growth that may have been offset in April. The Labor Department said openings fell 1.4 percent, to 3.8 million jobs. Total hiring declined 4.3 percent, to 4.3 million. On average, there were 3.1 unemployed people for each job opening. A ratio of 2-to-1 is typical in a healthy economy.
Home prices up
sharply in past year
Core Logic, a real estate data provider, on Tuesday said U.S. home prices rose 10.5 percent in March, compared with a year ago, the biggest gain since March 2006. Annual home prices have increased for 13 straight months. Prices are rising in part because more buyers are bidding on a limited supply of homes for sale, the company said.
Ford vans for rust
Auto safety regulators are monitoring about 100,000 Ford and Mercury minivans for rust problems that were not covered by a recall issued earlier this year. Ford recalled 230,000 Ford Freestar and Mercury Monterey minivans in March to fix rust in the wheel wells that can cause the third-row seats to come loose. The 2004-2007 vans were sold or registered in 20 cold-weather states and Canada.
Disney's 2Q net
Revenue gains at Disney's parks and movie studios led the company to a 32 percent increase in net income during the second quarter, topping analysts' expectations. Profits grew to $1.51 billion, or 83 cents per share. Revenue grew 10 percent, to $10.55 billion, the company reported Tuesday.
opens in SLC
CorePower Yoga will open its first studio in Salt Lake City, in Highland Square today. The studio offers two classroom areas, separate locker rooms and showers for men and women,and a waiting area. The studio is offering new customers one week of unlimited free yoga classes.
Baxter drug fails
to halt Azheimer's
Baxter International Inc. says that a blood product it was testing failed to slow mental decline or to preserve physical function in a major study of 390 patients with mild to moderate Alzheimer's disease. People who received 18 months of infusions with the drug, Gammagard, fared no better than others given a dummy solution, the company said Tuesday.